Prime Medicine Claims ‘Proof of Concept,’ but Lays Off Staff in Pivot

CRISPR pioneer Prime Medicine switches CEO and lays off quarter of its staff

Prime Medicine, a biotech whose wild ambitions for a powerful gene editing technology sank as the biotech market slumped, announced Monday it is replacing its CEO, laying off 25% of its staff, and scrapping its lead program. The reorganization comes amid a prolonged winter for the gene editing field that has seen nearly every major company lay off staff or cut programs, sometimes despite promising data. A few companies have shut down altogether …

Prime Medicine Announces Strategic Restructuring to Focus on Opportunities in Large Genetic Liver Diseases, Cystic Fibrosis, and Partnered Programs Alongside CEO Leadership Transition - Prime Medicine (NASDAQ:PRME)

- Initial positive data from Phase 1/2 clinical trial of PM359 in CGD provide clinical proof-of-concept for Prime Editing as a transformative gene editing technology -- -- On-track to file IND and/or CTA for Wilson's Disease and AATD programs in 1H 2026 and mid-2026, respectively; initial clinical data for both expected in 2027 -- -- Allan Reine, M.D., CFO, to succeed Keith Gottesdiener, M.D., as CEO; Jeff Marrazzo, member of the Board of Direct…

Prime Medicine claims ‘proof of concept,’ but lays off staff in pivot

CEO Keith Gottesdiener will be replaced by Prime's CFO as the company cuts 25% of its workforce and deprioritizes its lead program.

Prime Medicine Reduces Workforce by 25 Percent and Appoints David Schenkein as New CEO

Prime Medicine, a biotechnology company specializing in […] The post Prime Medicine Reduces Workforce by 25 Percent and Appoints David Schenkein as New CEO first appeared on GeneOnline News. The post Prime Medicine Reduces Workforce by 25 Percent and Appoints David Schenkein as New CEO appeared first on GeneOnline News.

Balyasny Asset Management L.P. Purchases New Holdings in Prime Medicine, Inc. (NYSE:PRME)

Balyasny Asset Management L.P. purchased a new stake in Prime Medicine, Inc. (NYSE:PRME – Free Report) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 16,342 shares of the company’s stock, valued at approximately $48,000. A number of other hedge funds […]

Prime Medicine Chops 25% of Workforce, Pivots Pipeline as CEO Quits

Keith Gottesdiener, MD, former president and CEO of Prime Medicine Prime Medicine is eliminating 25% of its workforce—about 50 jobs—in a restructuring that includes the company pivoting its prime editing-based pipeline focus to liver disease and programs funded by external collaboration partners, following the resignation of Keith Gottesdiener, MD, as president, CEO, and board member. Succeeding Gottesdiener is Prime Medicine’s CFO Allan Reine, …